Latigo Biotherapeutics, Inc. · NASDAQ:LTGO
James B. Tananbaum bought 140,000 Latigo Biotherapeutics, Inc. shares (Form 4)
Traded Aug 10, 2026 · Filed Aug 10, 2026
On Aug 10, 2026, James B. Tananbaum (Director, 10% owner) bought 140,000 Latigo Biotherapeutics, Inc. shares at US$18.00 for US$2.52M, leaving 3,414,544 shares. Filed Aug 10, 2026 (Form 4).
- Bought
- 140,000 shares
- Price
- US$18.00
- Value
- US$2.52M
- Holding after
- 3,414,544 shares (held indirectly)
- Trading plan
- No
- Role
- Director, 10% owner
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | Common Stock | Conversion | 445,320 | 3,562,984 | Indirect | |
| Aug 10, 2026 | Common Stock | Conversion | 1,125,823 | 1,125,823 | Indirect | |
| Aug 10, 2026 | Common Stock | Conversion | 742,201 | 1,868,024 | Indirect | |
| Aug 10, 2026 | Common Stock | Buy | 140,000 | US$18.00 | 2,008,024 | Indirect |
| Aug 10, 2026 | Common Stock | Conversion | 195,776 | 2,203,800 | Indirect | |
| Aug 10, 2026 | Common Stock | Conversion | 3,117,664 | 3,117,664 | Indirect | |
| Aug 10, 2026 | Common Stock | Conversion | 296,880 | 3,414,544 | Indirect |
Source
Related
- Latigo Biotherapeutics, Inc.
- James B. Tananbaum
- Latigo Biotherapeutics, Inc. shareholders
- Schedule 13G · AI Biotechnology LLC · Aug 18, 2026
- Schedule 13D · James B. Tananbaum · Aug 17, 2026
- Schedule 13G · Ra Capital Management, L.P. · Aug 17, 2026
- Schedule 13D · James B. Tananbaum · Aug 17, 2026
- Schedule 13G · Deep Track Capital, LP · Aug 13, 2026